Ajai Chari
LightNews LightNews
ajaichari.bsky.social
Ajai Chari
@ajaichari.bsky.social
140 followers 63 following 2 posts
Director of Multiple Myeloma Program and Professor of Clinical Medicine, University of California San Francisco. Views are my own.
Posts Replies Media Videos
Reposted by Ajai Chari
arvindsuresh1.bsky.social
How should we choose optimal salvage treatments following BCMA-directed CAR-T therapy in multiple myeloma?

Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team at @ucsfcancer.bsky.social #MMsm #myeloma

dx.doi.org/10.1080/1750...
Our strategy to address relapse after BCMA CAR T-cell therapy depends on whether a patient has rapid aggressive relapse (i.e., extramedullary disease, plasma cell leukemia, or rapidly rising myeloma markers or disease burden) or biochemical/clinical relapse without aggressive features. For all patients, talquetamab or another GPRC5D bispecific is a preferred approach. For rapid aggressive relapse, high dose cytotoxic chemotherapy or salvage autologous stem cell transplant may also be considered. For other relapses, a retrial of BCMA targeted therapy or various proteasome inhibitor and immunomodulatory drug combinations can be considered. The rapidly changing landscape of available drugs means that several novel approaches or clinical trials may also be available for patients.
October 18, 2025 at 2:29 AM
ajaichari.bsky.social
We are thrilled that the brilliant and innovative @simone-minnie will be joining UCSF myeloma program. She and her lab (positions open! aprecruit.ucsf.edu/JPF05438) will tackle some of the most pressing ?s in MM - mechanisms of T cell redirection resistance & optimal sequencing.
January 19, 2025 at 2:00 AM